Lonly thread here.
Another news release. Will this one soon catch investors attention?
newswire.ca
Letter from the President, Biotech Holdings Ltd. (OTC BB: BIOHF)
VANCOUVER, July 8 /CNW/ - The recently concluded meetings of the American
Diabetic Association in San Diego have brought a great deal of attention to
the fact that Type II or Adult Diabetes is one of the most serious health
issues facing growing millions of people, both in North America and around the
world. Type II Diabetes affects more than 15 million people in North America
and more than 200 million people worldwide, increasingly including people
under 40 and even affecting children and adolescents, as reported by CNN.
This gives particular significance to developments that are occurring
with Biotech Holdings' unique insulin-sensitizing Type II Diabetes drug, DIAB
II. DIAB II, which improves patients' ability to utilize insulin, the hormone
that regulates blood sugar levels, provides an effective long-term treatment
for Type II Diabetes symptoms.
I have never been more enthusiastic about Biotech's future. As a direct
result of the last two years of focussed pursuit of our international
marketing plan, we anticipate that DIAB II will become available to a growing
number of Type II diabetics. With three key distribution agreements in place
and more in final negotiation, Biotech has set an aggressive agenda for
commercial introduction of our product. Biotech's goals include accomplishing
the following in the coming months:
- Biotech expects to announce shortly the conclusion of a clinical
trial of DIAB II in Brazil. This trial is an important step in the
process of submitting DIAB II for approval in Brazil as a treatment
for Type II Diabetes.
- In addition to the submission of DIAB II for approval in Brazil,
Biotech will soon be making similar submissions in Argentina and
Venezuela. Licensing agreements have been signed with strong
pharmaceutical distributors in each of these countries which, together
with Brazil, have a total of over 15 million diabetics. Several other
similar drug distribution agreements are in various stages of
discussion or negotiation, with the goal of the strongest possible
distribution network for DIAB II in the Latin American region.
- Discussions are also underway with potential distributors for DIAB II
in the Middle East. It is anticipated that distribution agreements
will be finalized in the coming months.
- Biotech has recently decided to increase its emphasis on bringing
DIAB II to market in North America and Europe. Biotech expects to sign
an initial agreement with a major pharmaceutical company in the near
future.
Insulin-sensitizing drugs B which are projected to grow to $5 Billion
(US) in annual sales by 2003 B are the leading edge of new treatments for Type
II Diabetes. DIAB II's safety, efficacy and unique method of action make
Biotech's DIAB II of particular interest to pharmaceutical firms in North
America and around the world seeking to expand their presence in the
fast-growing Type II Diabetes market.
Biotech Holdings is at the beginning of a very active period in its
expansion. Biotech's goal is to bring a new safe and effective treatment to
those who have a daily battle with a degenerative disease that causes so much
suffering. At the same time, we believe that our progress in bringing DIAB II
to widespread commercial availability will soon produce significant benefits
for our shareholders.
Robert Rieveley
President, Biotech Holdings Ltd.
For inquiries, contact Austin Rand at Biotech Holdings Ltd.
1-888-216-1111 (toll-free), 8 a.m. to 5 p.m. Pacific time,
or by e-mail at biotech@direct.ca
Please visit Biotech's website at www.biotech.com
NOTE: This release contains forward-looking statements within the meaning
of Section 21E of the Securities and Exchange Act of 1934, as amended.
Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, actual results may differ for
reasons that include but are not limited to political and economic conditions
in the countries in which the Company does or intends to do business,
regulatory action, product pricing and competitive market conditions. These
forward-looking statements represent the Company's judgement at the date of
this release and any changes in assumptions or external factors could produce
significantly different results.
-30-
For further information: Austin Rand 1-888-216-1111 8 a.m. to 5 p.m.
Pacific time, biotech@direct.ca, www.biotechltd.com
BIOTECH HOLDINGS LTD. has 21 releases in this database. |
